Clinical Trials

Tucatinib

An orally bioavailable, selective inhibitor of HER2 -- a growth factor receptor that is over-expressed in multiple cancers, including breast, colorectal, esophageal, gastric, lung and ovarian cancers.
Our Pipeline Targets Large Cancer Indications
Read More >
Dedicated to Improving the Treatment of Cancer
Read More >

Tucatinib (also known as ONT-380)

Our lead development candidate, tucatinib, is an investigational, orally bioavailable, potent tyrosine kinase inhibitor (TKI) that is highly selective for HER2, also known as ErbB2, a growth factor receptor that is over-expressed in approximately 20% of breast cancers.

The following clinical trial is currently open for enrollment:

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

For more information on Cascadian Therapeutics-sponsored studies and investigator-sponsored trials of tucatinib, please visit ClinicalTrials.gov.

Our Pipeline Targets Large Cancer Indications
Read More >
Dedicated to Improving the Treatment of Cancer
Read More >